Effect of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status

This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of medical research Vol. 30; no. 1; pp. 452 - 8
Main Authors Xue, Yang, Zhang, YuTing
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 05.06.2025
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3 , CD4 , and CD4 /CD8 and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis.
AbstractList Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. Methods 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. Results The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3.sup.+, CD4.sup.+, and CD4.sup.+/CD8.sup.+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Conclusions Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis. Keywords: Freeze-dried powder of lactic acid bacteria, Pediatric bacterial peritonitis, Immune function, Nutritional status
This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3 , CD4 , and CD4 /CD8 and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis.
This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status.OBJECTIVESThis study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status.100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups.METHODS100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups.The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3+, CD4+, and CD4+/CD8+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment.RESULTSThe total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3+, CD4+, and CD4+/CD8+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment.Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis.CONCLUSIONSFreeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis.
Abstract Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. Methods 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. Results The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3+, CD4+, and CD4+/CD8+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Conclusions Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis.
This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status. 100 cases of bacterial peritonitis children from September 2020 to September 2021 were included and divided into a control group and an observation group using a randomized numerical table, with each group containing 50 cases. The control group was given routine treatment such as antimicrobial drugs, and the observation group was given adjuvant treatment of freeze-dried powder of lactic acid bacteria. The clinical efficacy, immune function, nutritional status, inflammatory response, intestinal dysbiosis, and endotoxin level were compared between the two groups. The total clinical effective rate of the observation group was higher than that of the control group. The ratio of CD3.sup.+, CD4.sup.+, and CD4.sup.+/CD8.sup.+ and the levels of ALB, TP, and Hb after treatment of the observation group were higher than those of the control group. CRP, PCT, and MCP-1 of the observation group were lower than those of the control group after treatment. Intestinal flora dysbiosis in the observation group was attenuated, and endotoxin level was reduced compared to the control group. No drug-related adverse reactions were observed in both groups during treatment. Freeze-dried powder of lactic acid bacteria can improve immune function and nutritional status, as well as reduce inflammatory response and intestinal flora dysbiosis in pediatric bacterial peritonitis.
ArticleNumber 452
Audience Academic
Author Xue, Yang
Zhang, YuTing
Author_xml – sequence: 1
  givenname: Yang
  surname: Xue
  fullname: Xue, Yang
– sequence: 2
  givenname: YuTing
  surname: Zhang
  fullname: Zhang, YuTing
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40474200$$D View this record in MEDLINE/PubMed
BookMark eNptkl1r1EAUhoNUbK39A15IQBBvUucrX1dSStVCwRsF74azM2d2pySZdWZS0d_gj_ak25ZdkBAyc87zvpmTvC-LoylMWBSvOTvnvGs-JMUY4xUTNd0tF5V4VpwIptqq7eSPo731cXGW0i3RrBFN2_cvimNFPSUYOyn-XjmHJpfBlS4i_sHKRo-23IZfFuNSHsBkb0ow3pYrWmP0UOaIkEec7oVbtB5yJOixP1At-hwmn30qw1T6cZwnLN08kRntYbLlNJNm2RGeMuQ5vSqeOxgSnj08T4vvn66-XX6pbr5-vr68uKmMUl2uDLdd19O7-r7tmbLC9A6A8dY1bJmG1ZbXqq0boZhERYUGpJItKLNCp2p5WlzvfG2AW72NfoT4Wwfw-r4Q4lpDpKEH1HUNzghYIXSktLh4QGtqzloOvWTk9XHntZ1XI1pD3yTCcGB62Jn8Rq_DneaCy15KTg7vHxxi-Dljynr0yeAwwIRhTloK3siGN50k9O0OXQOdzU8ukKVZcH3RKdFzqdRypPP_UHRZHL2hGDlP9QPBuz3BBmHImxSGefk56RB8sz_s05SPeSJA7AATQ0oR3RPCmV5yq3e51ZRbfZ9bLeQ_fZDhRg
Cites_doi 10.1016/j.jhep.2021.07.015
10.1097/MPH.0000000000001956
10.1016/j.intimp.2022.108729
10.1097/MEG.0000000000001109
10.1097/TIN.0000000000000332
10.3949/ccjm.90a.22028
10.1007/s12602-021-09895-0
10.1097/MEG.0000000000002524
10.1097/MD.0000000000019887
10.3390/nu15051141
10.1177/0049475520905745
10.1097/IPC.0000000000000853
10.1097/MEG.0000000000001709
10.14309/ajg.0000000000002155
10.1590/S0004-28032015000300008
10.1111/ijcp.13457
ContentType Journal Article
Copyright 2025. The Author(s).
COPYRIGHT 2025 BioMed Central Ltd.
The Author(s) 2025 2025
Copyright_xml – notice: 2025. The Author(s).
– notice: COPYRIGHT 2025 BioMed Central Ltd.
– notice: The Author(s) 2025 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s40001-025-02712-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2047-783X
EndPage 8
ExternalDocumentID oai_doaj_org_article_55afc2abea8f45dea4cba7c51071a930
PMC12139331
A842913440
40474200
10_1186_s40001_025_02712_2
Genre Randomized Controlled Trial
Journal Article
GroupedDBID ---
0R~
4.4
53G
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABUWG
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
DIK
EBD
EBLON
EBS
EMOBN
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PPXIY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7X8
5PM
PJZUB
PUEGO
ID FETCH-LOGICAL-c448t-c1d889bac997904d2c9faa017f60ffec05d1547562403e4ec06a3437a4cbef453
IEDL.DBID DOA
ISSN 2047-783X
0949-2321
IngestDate Wed Aug 27 01:29:07 EDT 2025
Thu Aug 21 18:25:31 EDT 2025
Fri Jul 11 17:09:31 EDT 2025
Tue Jun 17 21:55:27 EDT 2025
Tue Jun 10 03:43:12 EDT 2025
Tue Jun 10 02:10:33 EDT 2025
Thu Jun 19 02:16:00 EDT 2025
Thu Jul 17 06:05:14 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Freeze-dried powder of lactic acid bacteria
Pediatric bacterial peritonitis
Immune function
Nutritional status
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c448t-c1d889bac997904d2c9faa017f60ffec05d1547562403e4ec06a3437a4cbef453
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://doaj.org/article/55afc2abea8f45dea4cba7c51071a930
PMID 40474200
PQID 3216361683
PQPubID 23479
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_55afc2abea8f45dea4cba7c51071a930
pubmedcentral_primary_oai_pubmedcentral_nih_gov_12139331
proquest_miscellaneous_3216361683
gale_infotracmisc_A842913440
gale_infotracacademiconefile_A842913440
gale_healthsolutions_A842913440
pubmed_primary_40474200
crossref_primary_10_1186_s40001_025_02712_2
PublicationCentury 2000
PublicationDate 2025-06-05
PublicationDateYYYYMMDD 2025-06-05
PublicationDate_xml – month: 06
  year: 2025
  text: 2025-06-05
  day: 05
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle European journal of medical research
PublicationTitleAlternate Eur J Med Res
PublicationYear 2025
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References RE Popoiag (2712_CR6) 2021; 59
R Kullar (2712_CR8) 2020; 28
J Reyna-Figueroa (2712_CR16) 2021; 43
N Ubhi (2712_CR15) 2023; 35
M Griemsmann (2712_CR5) 2022; 76
CH Wang (2712_CR11) 2020; 99
N Honar (2712_CR7) 2015; 52
A Abdel-Razik (2712_CR13) 2018; 30
SSA Souza (2712_CR17) 2021; 2
S Khan (2712_CR1) 2023; 90
H Mittal (2712_CR4) 2020; 50
L Dong (2712_CR12) 2019; 8
L Fadin (2712_CR9) 2023
L Yang (2712_CR2) 2022; 108
P Termsinsuk (2712_CR10) 2020; 74
M Avadhanam (2712_CR14) 2023; 118
J Musoke (2712_CR20) 2020; 35
Z Chen (2712_CR19) 2023; 15
M Dibas (2712_CR3) 2020; 32
D Son (2712_CR18) 2023; 15
P Zito (2712_CR21) 2022; 2
References_xml – volume: 76
  start-page: 230
  issue: 1
  year: 2022
  ident: 2712_CR5
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.07.015
– volume: 43
  start-page: e457
  issue: 4
  year: 2021
  ident: 2712_CR16
  publication-title: J Pediatr Hematol Oncol
  doi: 10.1097/MPH.0000000000001956
– volume: 8
  start-page: 4
  year: 2019
  ident: 2712_CR12
  publication-title: Clin Med
– volume: 108
  year: 2022
  ident: 2712_CR2
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2022.108729
– volume: 30
  start-page: 779
  issue: 7
  year: 2018
  ident: 2712_CR13
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0000000000001109
– year: 2023
  ident: 2712_CR9
  publication-title: Topics Clin Nutr
  doi: 10.1097/TIN.0000000000000332
– volume: 2
  start-page: 70
  year: 2022
  ident: 2712_CR21
  publication-title: J Investig Med
– volume: 90
  start-page: 209
  issue: 4
  year: 2023
  ident: 2712_CR1
  publication-title: Cleve Clin J Med
  doi: 10.3949/ccjm.90a.22028
– volume: 15
  start-page: 821
  issue: 4
  year: 2023
  ident: 2712_CR19
  publication-title: Probiotics Antimicrob Proteins
  doi: 10.1007/s12602-021-09895-0
– volume: 35
  start-page: 384
  issue: 4
  year: 2023
  ident: 2712_CR15
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0000000000002524
– volume: 59
  start-page: 345
  issue: 4
  year: 2021
  ident: 2712_CR6
  publication-title: Rom J Intern Med
– volume: 99
  issue: 21
  year: 2020
  ident: 2712_CR11
  publication-title: Medicine
  doi: 10.1097/MD.0000000000019887
– volume: 15
  start-page: 1141
  issue: 5
  year: 2023
  ident: 2712_CR18
  publication-title: Nutrients
  doi: 10.3390/nu15051141
– volume: 50
  start-page: 138
  issue: 2
  year: 2020
  ident: 2712_CR4
  publication-title: Trop Doct
  doi: 10.1177/0049475520905745
– volume: 28
  start-page: 123
  issue: 3
  year: 2020
  ident: 2712_CR8
  publication-title: Infect Dis Clin Pract
  doi: 10.1097/IPC.0000000000000853
– volume: 32
  start-page: 1075
  issue: 9
  year: 2020
  ident: 2712_CR3
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0000000000001709
– volume: 118
  start-page: 613
  issue: 4
  year: 2023
  ident: 2712_CR14
  publication-title: Am J Gastroenterol
  doi: 10.14309/ajg.0000000000002155
– volume: 2
  start-page: 10
  year: 2021
  ident: 2712_CR17
  publication-title: Current Dev Nutr
– volume: 35
  start-page: 104
  issue: 1
  year: 2020
  ident: 2712_CR20
  publication-title: S Afr J Infect Dis
– volume: 52
  start-page: 195
  issue: 3
  year: 2015
  ident: 2712_CR7
  publication-title: Arq Gastroenterol
  doi: 10.1590/S0004-28032015000300008
– volume: 74
  issue: 3
  year: 2020
  ident: 2712_CR10
  publication-title: Int J Clin Pract
  doi: 10.1111/ijcp.13457
SSID ssj0000626799
Score 2.38797
Snippet This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and...
Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune...
Abstract Objectives This study was to investigate the effects of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 452
SubjectTerms Bacteria
Bacterial Infections - immunology
Bacterial Infections - therapy
Care and treatment
Child
Child, Preschool
Dysbiosis
Female
Freeze Drying
Freeze-dried powder of lactic acid bacteria
Gastrointestinal Microbiome
Health aspects
Humans
Immune function
Infant
Lactobacillales
Male
Microbiota (Symbiotic organisms)
Nutritional Status
Pediatric bacterial peritonitis
Pediatrics
Peritonitis
Peritonitis - immunology
Peritonitis - microbiology
Peritonitis - therapy
Powders
Probiotics - administration & dosage
Probiotics - therapeutic use
Treatment Outcome
Title Effect of freeze-dried powder of lactic acid bacteria treatment of pediatric bacterial peritonitis on immune function and nutritional status
URI https://www.ncbi.nlm.nih.gov/pubmed/40474200
https://www.proquest.com/docview/3216361683
https://pubmed.ncbi.nlm.nih.gov/PMC12139331
https://doaj.org/article/55afc2abea8f45dea4cba7c51071a930
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtCqWX0nfcplsVCj0UEVuSJfm4KQlhIaG0DexNyJZMF4K97INCfkN-dGfkB2t66KUngzQYS9-MZgbPfCLkU55zFTKnGYTihknpOXOyTFld-0wHbkIZe2GurtXljVws8-XBVV9YE9bRA3cbd5rnrq64K4Mztcx9cLIqna5AlXTmChGzdfB5B8lUdwZzpYti6JIx6nQr01g9xLEhWWec8YknioT9fx_LB35pWjN54IQunpGnffRI591XPycPQvOCPL7q_4-_JPcdGTFta1pvQrgLzEMq7Om6_e3DBodvY1MUddXK07JjanZ0rDZHifVwecc4f0uRDnmH1r_a0rahK2wqCRR9IuJKXeNpM9D6gzh2Ke23r8jNxfnPr5esv2-BVZCk7ViVeWMKeHdR6CIF2Kqidg5MtlYpfn2aewi4NERMMhVBwoByQgqNkAQAR7wmR03bhGNCIc5wSJUnU1lK56VzuZJZLXlQHrUjIV-GvbfrjlbDxnTEKNshZQEpG5GyPCFnCM8oiZTYcQAUxfaKYv-lKAn5gODarr90NGw7N-CSMyElSHyOEmjagHHl-g4FWBKSZE0kTyaSYJLVZPrjoEAWp7COrQntfmsFh_hXZcqIhLzpFGpcFeyVlnBoJcRMVG2y7OlMs_oVGcGRl68QInv7PzbqHXnCo5koluYn5Gi32Yf3EHntyhl5qJd6Rh7N54sfC3ienV9_-z6LpvcH-vQyJw
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+freeze-dried+powder+of+lactic+acid+bacteria+treatment+of+pediatric+bacterial+peritonitis+on+immune+function+and+nutritional+status&rft.jtitle=European+journal+of+medical+research&rft.au=Xue%2C+Yang&rft.au=Zhang%2C+YuTing&rft.date=2025-06-05&rft.issn=2047-783X&rft.eissn=2047-783X&rft.volume=30&rft.issue=1&rft_id=info:doi/10.1186%2Fs40001-025-02712-2&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s40001_025_02712_2
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-783X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-783X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-783X&client=summon